Serca Pharmaceuticals

Serca Pharmaceuticals is a Norwegian biotechnology company dedicated to developing first-in-class treatments for heart failure. The company's primary focus is on a small molecule activator of the SERCA2a enzyme, which is responsible for calcium transport in cardiac muscle cells and is often downregulated in failing hearts. By restoring calcium homeostasis, Serca's therapeutic approach aims to improve both the contraction and relaxation of the heart muscle. Founded as a spin-off from the University of Oslo and Oslo University Hospital, the company leverages deep expertise in cardiovascular biology to address significant unmet needs in heart failure with reduced ejection fraction.